Result of AGM

Released : 25 May 2017 11:49

RNS Number : 2485G
Amryt Pharma PLC
25 May 2017
 

 

25 May 2017

AIM: AMYT

ESM: AYP

 

Amryt Pharma plc

("Amryt" or the "Company")

 

Result of AGM

 

Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, is pleased to announce that all resolutions proposed at the Company's Annual General Meeting, held today, were duly approved by shareholders.

 

 

 

Enquiries:

 

Amryt Pharma plc

C/o KTZ Communications

Joe Wiley, CEO

Rory Nealon, CFO/COO




Shore Capital

+44 (0) 20 7408 4090

Nomad and Joint Broker


Bidhi Bhoma, Edward Mansfield




Davy

+353 (1) 679 6363

ESM Adviser and Joint Broker


John Frain, Anthony Farrell




Stifel

+44 (0) 20 7710 7600

Joint Broker


Jonathan Senior, Ben Maddison




KTZ Communications

+44 (0) 20 3178 6378

Katie Tzouliadis, Emma Pearson


 

 

 

 

About Amryt Pharma plc

(www.amrytpharma.com)

 

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

 

The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the EU and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels leading to aggressive and premature narrowing and blocking of arterial blood vessels.  If left untreated, heart attack or sudden death may occur in childhood or early adulthood. 

 

Amryt's lead drug candidate, AP101 (Episalvan), is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment.  It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

 

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. 

 

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGEAESSALSXEFF